Approval · Notice of Compliance 3431 · 2003
ZYPREXA: Notice of Compliance 3431
Issued March 17, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3431
- Date
- March 17, 2003
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for the treatment of acute bipolar mania
- Therapeutic class
- Antipsychotic/antimanic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZYPREXA | Not yet assigned | — |
| ZYPREXA ZYDIS | Not yet assigned | — |
Medicinal ingredients
- OLANZAPINE 2.5 MG per TAB
- OLANZAPINE 5 MG per TAB
- OLANZAPINE 7.5 MG per TAB
- OLANZAPINE 10 MG per TAB
- OLANZAPINE 15 MG per TAB
- OLANZAPINE 20 MG per TAB